Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2295550 | 0.89 | KMT2A (0.60) | MEN1KMT2ATSHRALDH1A1LMNA | |
| SCHEMBL5875625 | 0.89 | TSHR (0.57) | MEN1KMT2APOLBTSHRKDM4E | |
| SCHEMBL4551788 | 0.89 | POLB (0.60) | MEN1KMT2APOLBTSHRKDM4E | |
| SCHEMBL18891204 | 0.88 | TSHR (0.56) | MEN1KMT2APOLBTSHRKDM4E | |
| Hydrochloric Acid SCHEMBL6196657 | 0.88 | POLB (0.61) | MEN1KMT2APOLBTSHRKDM4E | |
| SCHEMBL13173304 | 0.87 | KMT2A (0.57) | MEN1KMT2APOLBTSHRALDH1A1 | |
| SCHEMBL18430905 | 0.87 | TSHR (0.55) | MEN1KMT2APOLBTSHRKDM4E | |
| SCHEMBL5827157 | 0.87 | CYP2C9 (0.65) | MEN1KMT2APOLBTSHRKDM4E | |
| SCHEMBL6993844 | 0.87 | POLB (0.61) | MEN1KMT2APOLBTSHRKDM4E | |
| Hydrochloric Acid SCHEMBL6196650 | 0.87 | POLB (0.58) | MEN1KMT2APOLBTSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011154798-A1 | NOVEL 1,4-DIAZEPAM PDE-5 INHIBITOR DERIVATIVES | WORLD-TRADE IMPORT-EXPORT WTIE, AG (CH) | 2011-12-15 | — | — | WO | disclosed |
| US-7005520-B2 | Process for the preparation of pyrazolopyrimidinones | PFIZER INC. (US) | 2006-02-28 | — | — | US | disclosed |
| EP-1292586-B1 | PROCESS FOR THE PREPARATION OF PYRAZOLOPYRIMIDINONES | PFIZER LTD (GB) | 2004-08-04 | — | — | EP | disclosed |
| US-20040106796-A1 | Novel process for the preparation of pyrazolopyrimidinones | PFIZER INC | 2004-06-03 | — | — | US | disclosed |
| US-6667398-B2 | Reacting a benzamidine compound with a amide substituted pyrazole compound | PFIZER INC | 2003-12-23 | — | — | US | disclosed |
| EP-1292586-A1 | PROCESS FOR THE PREPARATION OF PYRAZOLOPYRIMIDINONES | Pfizer Limited (GB) | 2003-03-19 | — | — | EP | disclosed |
| US-20020013464-A1 | Novel process for the preparation of pyrazolopyrimidinones | PFIZER INC. | 2002-01-31 | — | — | US | disclosed |
| WO-2001098284-A1 | PROCESS FOR THE PREPARATION OF PYRAZOLOPYRIMIDINONES | PFIZER LIMITED (GB) | 2001-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106796-A1 | Novel process for the preparation of pyrazolopyrimidinones | CYP4F3, CYP3A4, NDUFS3 | MEN1 2804/4885KMT2A 3952/4885POLB 2081/4885 |
| US-20020013464-A1 | Novel process for the preparation of pyrazolopyrimidinones | CYP4F3, CYP3A4, NDUFS3 | MEN1 2804/4885KMT2A 3952/4885POLB 2081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.